---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000089"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:21:58.905291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial

## Summary
- Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.
- ALLO-715 in MM expansion (FCA60): 67% ORR, 42% VGPR+ (all MRD-negative), median DOR 9.2 months, longest 24 months.
- ALLO-316 in RCC CD70+ patients (n=9): 100% disease control, 33% partial responses; generally manageable safety.
- Phase 2 ALPHA2 trial enrolling ~100 LBCL patients; planning pivotal Phase 2 for ALLO-715 and evaluating ALLO-316 expansion.
- Research update: Dagger technology aims to delay AlloCAR T rejection; ALLO-605 trial paused for manufacturing review.

## SEC filing metadata
- accession: 0001737287-22-000089
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/0001737287-22-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/allo-20221129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000089
- JSON: https://secwatch.observer/filing/0001737287-22-000089.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.